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Genome-wide association studies can help identify multi-gene contributions to disease. As the number of high-density genomic mark-
ers tested increases, however, so does the number of loci associated with disease by chance. Performing a brute-force test for the inter-
action of four or more high-density genomic loci is unfeasible given the current computational limitations. Heuristics must be employed
to limit the number of statistical tests performed.
In this paper we explore the use of biological domain knowledge to supplement statistical analysis and data mining methods to iden-
tify genes and pathways associated with disease. We describe Pathway/SNP, a software application designed to help evaluate the asso-
ciation between pathways and disease. Pathway/SNP integrates domain knowledge—SNP, gene and pathway annotation from multiple
sources—with statistical and data mining algorithms into a tool that can be used to explore the etiology of complex diseases.
 2007 Elsevier Inc. All rights reserved.
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This paper describes Pathway/SNP, a software applica-
tion that allows its user to utilize pathway data in the anal-
ysis of high-density genomic SNP data derived from
disease association studies. Our goal in building Path-
way/SNP is to allow the user to explore ﬂexibly the etiol-
ogy of disease using diﬀerent statistical and data mining
algorithms. The task of utilizing pathway data to help in
the interpretation of genomic SNP data is complex. There
are many statistical and data mining approaches that can
be applied, and new approaches are being developed. There1532-0464/$ - see front matter  2007 Elsevier Inc. All rights reserved.
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E-mail address: valentin.dinu@yale.edu (V. Dinu).is no single approach that is in some sense best. Diﬀerent
approaches may work better with diﬀerent data sets and
with diﬀerent diseases. As a result, it is important to pro-
vide the user with a ﬂexible set of tools that allow diﬀerent
approaches to be tried incrementally and interactively.
Indeed, the challenge of using pathway knowledge to
assist in the interpretation of genomic SNP association
data is one instance of a broader challenge. There are large
amounts of very diverse biological knowledge being gener-
ated that can potentially be used integratively to help
analyze high-throughput data. Examples include pathway
information, tissue and cellular component localization,
gene expression information, and regulatory networks.
This knowledge can help drive the analysis of genomic data
for many diﬀerent purposes. In the case of Pathway/SNP,
the purpose is to analyze the underlying etiology of disease
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same time, there is a wide range of useful statistical and
data mining approaches that can be used when integrating
biological knowledge in the analysis of such genomic data.
The goals of this paper are (1) to describe the current
implementation of Pathway/SNP and its functionality, (2)
to discuss some of the lessons learned during its implemen-
tation concerning the use of diﬀerent statistical and data
mining algorithms, and (3) to discuss some of the implica-
tions for building interactive tools in the future that allow
such algorithms to be ﬂexibly adapted to integrative geno-
mic analysis.
2. Background
Over the past decade, many studies have used micro-
arrays to analyze gene expression proﬁles associated with
disease, most notably cancer [1–3]. Over the past 3 years,
newly developed high-density single nucleotide polymor-
phism (SNP) microarray technology has brought within
reach the promise of performing genome-wide association
(GWA) studies to identify genomic mutations that are
associated with a wide range of diseases. The results from
several successful GWA studies have already been pub-
lished, identifying mutations linked to age related macular
degeneration (AMD) [4] and type 1 diabetes [5]. Other
large-scale GWA studies are in progress, e.g., Welcome
Trust Case Control Consortium’s analysis of 19,000
DNA samples at 675,000 genome-wide SNPs [6].
Complex diseases, e.g., diabetes, hypertension, Alzhei-
mer’s disease, and AMD, are believed to be caused by
the interaction of multiple genes and environmental fac-
tors. The number of mathematical operations required to
assess the association between multiple interacting genomic
loci and disease grows exponentially with the number of
interacting SNPs. Simple arithmetic calculations (Appen-
dix A) show that even with the most powerful supercom-
puters available today it is computationally impossible to
perform a comprehensive test of association for four or
more interacting SNPs when analyzing data sets for several
hundred individuals and several hundred thousands SNPs.
As a result, a variety of statistical, computational, heuris-
tic, and knowledge-based approaches (often combined)
must be developed to compensate for the inability to per-
form all potentially desirable computations.
Various statistical approaches to addressing the issue of
multiple genomic loci association with quantitative traits
(e.g., diseases) have shown interesting, if sometimes incon-
clusive, results. Storey and colleagues recently proposed a
computationally eﬃcient stepwise algorithm to identify
genetic loci associated with gene expression in yeast [7].
In this algorithm, at each step the genomic locus with the
strongest association to the trait is selected from the entire
set of loci. The authors found, to their surprise, that the
stepwise method was more powerful than the exhaustive
method performing the association test over all pairs of
loci. The authors acknowledged, however, that theirmethod could miss locus pairs with primarily epistatic
(and little individual locus) eﬀect on the trait [7]. In another
recent study, Marchini and colleagues [8] concluded that
the determination of one single best strategy in a multi-
locus disease association model might not be possible. Dif-
ferent strategies can perform better in diﬀerent conditions
based on varying parameters such as allele frequencies or
locus interaction models (e.g., additive vs. multiplicative
eﬀects). Moreover, the authors determined that the same
varying parameters can aﬀect the ability to replicate the
association of interacting loci across diﬀerent studies.
Using a set of simulated data, the authors found that in
the largest fraction of conﬁgurations tested, the compre-
hensive testing of all paired loci interactions had the high-
est statistical power [8].
Roeder and colleagues [9] recently proposed integrative
analysis using genetic linkage data to weigh the association
p-values. The authors proposed dividing the association p-
values by weights that are larger than 1 in regions previ-
ously linked with the disease and smaller than 1 in unlinked
regions. Similarly, the use of biological knowledge, such as
pathway information, can help researchers focus on genes
involved in processes known to be related to disease. Such
thinking underlies many candidate gene association analy-
ses. For example, a recent investigation attempted to use
pathway level information to model the association
between various genes and disease and the interaction
among genes, and between genes and environmental fac-
tors [10]. In another recent study, Schaid and colleagues
proposed a non-parametric test of association between dis-
ease and a set of pathway genes using U-statistics [11]. The
authors applied their method to investigate the association
between prostate cancer and a group of several dozen SNPs
selected from two metabolic pathways (androgen and
estrogen response elements). In this example, the authors
determined that their method could identify the combined
disease association of multiple markers with small eﬀects
while a single locus association was not signiﬁcant after
Bonferroni correction for multiple testing. There are anal-
ogous eﬀorts in functional genomic studies to use pathway
information to better understand disease etiology [12,13].
A number of data mining approaches, such as dimen-
sionality reduction [14,15], neural networks [16,17], ran-
dom forests [18], and support vector machines (SVM)
[19,20], have also been proposed for multi-locus associa-
tion with traits. Data mining approaches are well-suited
for identifying trends in large dimensional data sets. Some,
however, can be computationally intensive (e.g., SVM,
neural networks) and some may be hard to interpret
(e.g., neural networks).
One conclusion that can be drawn from these previous
studies is that the ‘‘one model ﬁts all’’ approach is likely
not optimal when analyzing the association between geno-
mic loci and disease. We developed Pathway/SNP, a soft-
ware tool that allows an exploratory approach to
integrative association analysis, combining the use of bio-
logical pathway information and diﬀerent statistical and
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information, gene annotation, and SNP location to identify
the pathways that are the most strongly associated with
disease. The association between a pathway and disease
can be quantiﬁed by z-scores generated by U-statistics, or
by the percent of correct disease class assignments using
data mining algorithms. The users can further drill down
on speciﬁc pathways to explore which genomic loci
contributed most to the pathway association score by
performing association tests solely on one pathway’s SNPs.
The statistical signiﬁcance can be assessed via permutation-
based false discovery rate (FDR).3. System description
This section describes the Pathway/SNP system and its
various components. A later section then provides an
example of how the system was used to analyze an example
data set.3.1. Design objectives
Pathway/SNP is designed as an exploratory tool. It
must be able to perform basic operations such as perform-
ing an association test using a desired algorithm, displaying
and sorting results. For more advanced exploration, users
can modify algorithm parameters or ﬁlter the input SNPs
to be analyzed (e.g., based on MAF) and/or the patients
to be analyzed (e.g., based on disease stage, if such infor-
mation is available).
The response time must be fast for simple queries such
as single SNP or single pathway association tests. SinceFig. 1. Pathway/SNP’ssome algorithms can be computationally intensive (e.g.,
data mining algorithms such as neural networks, SVM or
Random Forests, or FDR calculation using a large number
of permutations), the users can choose to have those results
saved to the ﬁle system and be notiﬁed via email about job
completion.
The biological annotation data must be well curated and
up to date. For example, since the reference human genome
build changes over time, the SNP and gene annotations
must be appropriately labeled with the diﬀerent genome
builds on which they are based.3.2. Architecture
Pathway/SNP is written in Java and has a 3-tier archi-
tecture (Fig. 1): (1) presentation tier (GUI written in Java
Server Pages (JSP) and accessible via a standard Internet
browser); (2) logic tier (statistical and data mining algo-
rithms written in Java); and (3) data tier (genotype, pheno-
type and annotation data stored in a heavily indexed
relational database). The 3-tier architecture allows for ﬂex-
ibility in deployment. The application can be installed and
run on a stand alone computer, or it can run on a parallel
computing cluster to meet scalability requirements.3.3. Biological data
The pathway annotation data are loaded in the applica-
tion database. There are currently annotations for 561
pathways: 181 KEGG [21], 314 BioCarta [22] and 66 Gen-
MAPP [23] human pathways. Some of these pathways
overlap. For example, KEGG contains a ‘‘complement3-tier architecture.
Fig. 2. A schematic of the Complement and Coagulation Cascades Pathway. Source: KEGG Database website [21].
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sponding information is represented in BioCarta under
multiple pathways: ‘‘alternative complement pathway,’’
‘‘classical complement pathway,’’ ‘‘lectin induced comple-
ment pathway,’’ ‘‘complement pathway’’ (including the
ﬁrst three), ‘‘ﬁbrinolysis pathway,’’ ‘‘cells and molecules
involved in local acute inﬂammatory response,’’ etc. Some
pathway annotation sources are constantly evolving (e.g.,
KEGG is re-built nightly, with new additions or modiﬁca-
tions performed quite frequently), while others are less
often updated. Pathway/SNP users have the option of con-
necting straight to the pathway annotation servers, such as
KEGG’s web service server [24], to use in analysis the most
recent pathway information. Exercising this option can
increase the total time of execution. It takes about 30 min
to retrieve the annotation data for 181 pathways directly
from the KEGG web service server using the SOAP API.
The gene annotation data are loaded locally from
NCBI’s Entrez Gene [25]. The Aﬀymetrix 100k and 500k
GeneChip microarray annotation ﬁles are preloaded in
the database. Annotations for any additional microarrayplatforms (e.g., Illumina HumanHap550) can also be
loaded into the database. The annotations for genes and
SNPs involve genomic positions, which change when new
human genome references are released. As a result, one
needs to keep track of the diﬀerent genome releases to
which the annotations apply in order to avoid mixing data
from diﬀerent genome builds.
By default, SNPs are considered relevant to a given bio-
logical pathway in Pathway/SNP if they are within 10,000
base pairs (bp) of a pathway gene’s location. (Users may
modify this default distance.) Using this default distance,
for example, we identiﬁed 94 SNPs on the Aﬀymetrix
100k GeneChip that were in the vicinity of 46 complement
pathway genes.
Additionally, users can create their own sets of genes or
SNPs to be used in analysis. They can store sets of genes
as ‘‘manually curated’’ pathways in the database, or they
can directly use sets of genes or sets of SNPs in the
database queries. For example, the set of 46 complement
pathway genes mentioned above is ‘‘manually curated’’
in the sense that we started with the genes in the
754 V. Dinu et al. / Journal of Biomedical Informatics 40 (2007) 750–760complement pathway in the KEGG database and we aug-
mented it with genes selected from literature and Entrez
Gene [26].
The genotype and patient information are stored in the
database using the entity-attribute-value (EAV) data mod-
eling approach. As a result, the database schema does not
need to change when loading experimental data from stud-
ies that use diﬀerent types of patient-descriptive data. The
SNP information, however, is stored in conventional rela-
tional tables. As a result, the database uses a mixed schema
data model [27].
3.4. Algorithms
The algorithms included in Pathway/SNP can be
roughly divided into three categories: (1) single SNP asso-
ciation with disease, (2) pathway association with disease,
and (3) permutation-based statistical signiﬁcance inference.
We started the development of Pathway/SNP by ﬁrst
implementing simpler algorithms, for single SNP associa-
tion with disease, and gradually expanded to include more
complex algorithms capable of incorporating biological
domain knowledge. Additional algorithms could be added
in the future, e.g., Fisher’s exact test for single SNP associ-
ation analysis, other data mining algorithms and/or
packages.
3.4.1. Single SNP association with disease
We have included two algorithms for the exploration of
association between single SNPs and disease: chi square
and Armitage’s trend test [28]. These algorithms do not uti-
lize SNP, gene or pathway annotation and simply assess
each individual’s SNP association with disease using the
basic genotype data, without regard to the SNP’s genomic
information such as neighboring SNPs or genes. These
algorithms can be applied to one SNP at a time or to all
genotyped SNPs at once.
The chi square test can be allele-based, using a 2 · 2 con-
tingency table: (case, control) · (allele A count, allele B
count), or it can be genotype-based, using a 2 · 3 contin-
gency table: (case, control) · (genotype AA count,
genotype AB count, genotype BB count). Since the
allele-based chi square statistic has 1 degree of freedom,
it is generally preferred over the genotype-based chi square
statistic that has 2 degrees of freedom.
Armitage’s trend test [28] is a more complex algorithm
that allows the user to explore diﬀerent models of associa-
tion between a SNP and disease. For example, an additive
interaction model can be speciﬁed by using the following
multipliers: 0 for homozygous non-risk alleles, 1 for hetero-
zygous alleles, 2 for homozygous risk alleles. Similarly, a
dominant interaction model can be speciﬁed by using mul-
tipliers 0, 1, and 1, while a recessive model can use 0, 0, and
1, respectively. The trend test statistic has 1 degree of
freedom.
Any statistical result obtained from using either of the
association tests on multiple SNPs must then be adjustedin order to account for bias introduced by the multiple
testing (e.g., there are m = 116,204 SNPs on the Aﬀyme-
trix 100k GeneChip). One can apply this correction by
using the Bonferroni adjustment (roughly, by multiplying
the p-value by the value of markers tested, m), or by uti-
lizing the FDR procedure described in Section 3.4.4.
3.4.2. U-statistics for pathway association with disease
We have implemented the non-parametric algorithm
based on U-statistics proposed by Schaid and colleagues
[11]. Brieﬂy, the algorithm allows the use of diﬀerent ker-
nels (e.g., recessive, dominant and linear dosage) to
explore the association between a set of SNPs (e.g., path-
way SNPs) and disease. It also accounts for the correla-
tion between genomic markers found in linkage
disequilibrium (LD) by using weights for each marker.
The weighted eﬀects over all genetic markers are summed
into a global statistic with one degree of freedom. The
resulting z-scores can be used to rank pathways and also
to calculate an approximate p-value (after adjusting for
multiple testing). An alternative method provided for
calculating statistical signiﬁcance using permutation tests
is described below in the FDR section. This algorithm can
be used to explore the statistical likelihood that a given
pathway might be associated with the disease being
investigated.
3.4.3. Data mining
Data mining classiﬁers (e.g., tree-based, Random For-
ests, logistic, SVM) can be used to explore the association
between pathways and disease. The ‘‘percent correct’’
classiﬁcation of cases and controls estimated with the
genotypes at the pathway SNPs can be used as a statistic
for measuring the association between pathways and
disease.
We have incorporated the data mining algorithms from
the well known Weka data mining program [23,29]. The
classiﬁers are run by default with a 10-fold cross validation.
The users, however, can modify any of the default param-
eters used when running the data mining algorithms. As
with most statistical and data mining tools, users would
need to be well trained in machine learning/data mining
techniques to properly tune the parameters of the data min-
ing algorithms. More advanced users can use any of the
Weka functionality that can be invoked from the command
line, such as clustering, feature selection or ‘‘meta-learn-
ing’’ algorithms [29].
The statistical signiﬁcance of the pathway association
scores can be assessed by FDR, as described below.
3.4.4. Statistical signiﬁcance using permutation-based FDR
The statistical signiﬁcance of association scores between
individual SNPs or pathways with disease can be estimated
using permutation-based FDR. The algorithm can use any
statistics such as scores generated by the chi square test, U-
statistics, or the percent-correct classiﬁcation scores gener-
ated by the data mining classiﬁers. The aim of the FDR
Table 1
Possible outcomes from m hypothesis tests
Accept Reject Total
Null hypotheses true U Va m0
Alternative hypotheses true Qb S m1
Total W Rc m
a V, number of type I errors (false positives).
b Q, number of type II errors (false negatives).
c R, total number of null hypotheses rejected.
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the proportion of type I errors (false positives) among all
signiﬁcant results: FDR = E(V/R) using the notation from
Table 1. When multiple genes or pathways may be involved
in disease etiology, this procedure may yield higher statisti-
cal power compared to family wise error rate (FWER) pro-
cedures, such as Bonferroni, which control at a desired
level a the probability of having at least one type I error:
FWER = P(VP 1). For FDR, using a statistic Ti for each
pathway, one chooses a cutoﬀ point C and selects as signif-
icant all pathways satisfying Ti > C. C is chosen in order to
control FDR at the desired level a.
The details of the FDR algorithm implementation in
Pathway/SNP are provided in [26]. Brieﬂy, the algorithm
performs a large number (e.g., 1000) of random permuta-
tions of the patient labels and for each pathway the
‘‘random’’ scores (log10 from the p-values derived using
U-statistics, or the fraction of correct classiﬁcations using
the data mining algorithms) are recorded. The original
(using the unrandomized data) pathway scores are used
as cutoﬀs and the fraction of random scores that are above
each cutoﬀ is calculated. This fraction is the FDR, or the so
called q-value [31]. Pathways with a low FDR, e.g., below a
threshold of 0.05, are considered signiﬁcant.4. Sample results illustrating the user of Pathway/SNP
4.1. A hypothetical use case scenario
For illustration purposes, we start by describing a hypo-
thetical use case scenario for the use of Pathway/SNP. A
user, e.g., a genetic epidemiologist, intends to perform
association analysis with a disease using 1000 controls
and 1000 cases, genotyped with the Aﬀymetrix 500k micro-
array. The data set has approximately 109 data points
(500,000 genotypes · 2000 individuals).
The ﬁrst analysis she performs is single SNP associa-
tion with disease, aimed at identifying genomic loci that
are signiﬁcantly associated with the disease. No signiﬁ-
cant p-values are identiﬁed after adjusting for multiple
testing.
She then performs a pathway based association with dis-
ease, aimed at identifying pathways that are signiﬁcantly
associated with the disease. She selects the J48 (Weka’s
implementation of C4.5) tree-based classiﬁcation algorithm
and chooses to ﬁnd the statistical signiﬁcance by perform-ing 1000 permutations. The result displays a list of over 500
pathways, sorted by the statistical signiﬁcance of the dis-
ease association scores. The top two pathways are statisti-
cally signiﬁcant. One of the pathways is biologically
relevant and there is literature pointing to the possible
involvement of the pathway in the disease process.
Focusing on that pathway, the user then performs a sin-
gle SNP disease association test only for the SNPs in that
pathway to identify the SNPs and the genes that contribute
to the high pathway association score.
4.2. Using Pathway/SNP to analyze the AMD data set
We used Pathway/SNP to analyze a data set used in a
previously published GWA study [4]. The original analysis
had identiﬁed a mutation in CFH, a complement pathway
gene, as strongly associated with AMD [4], using the single
SNP association test. This association has since been con-
ﬁrmed in many other studies and is believed to have an
AMD population attributable risk of about 60% [32].
The data set consisted of 50 controls and 96 AMD cases
(50 dry AMD, 46 wet AMD) that were genotyped using
the Aﬀymetrix 100k GeneChip. The details of our subse-
quent analysis can be found in [26].
We ﬁrst performed the single SNP association test to
replicate the results previously published. As illustrated in
Fig. 3, the top 2 scoring SNPs (out of more than
100,000) were indeed the ones situated in the intron of
CFH and previously identiﬁed as strongly associated with
AMD.
We then performed a pathway based association analy-
sis. We used U-statistics with ﬁve kernels: dominant, reces-
sive, linear, quadratic, allele match; and four data mining
algorithms: J48 (C4.5), Random Forests, SVM, and Naı¨ve
Bayes. Since the AMD patients were divided into two cat-
egories—wet AMD and dry AMD—we performed the tests
by grouping the patients in various categories: control vs.
all cases, control vs. wet AMD, control vs. dry AMD,
dry AMD vs. wet AMD. We ran the computationally
intensive data mining algorithms in a cluster environment.
Fig. 4 illustrates a sample result from one of the pathway
association tests, with pathways ranked according to the
statistical scores. While the results were relatively diﬀerent
for the various U-statistics kernels and data mining algo-
rithms, several pathways had signiﬁcant statistical scores
in multiple tests. Some of these pathways were relevant
to AMD: complement pathway [33–35], mitochondrial
fatty acid beta oxidation [36,37], calcium regulation and
signaling [38,39].
We performed a more in depth analysis for the associa-
tion between the complement pathway SNPs and AMD.
We stratiﬁed the individuals based on the CFH SNP geno-
type and identiﬁed a striking pattern based on two comple-
ment pathway genes, C7 and MBL2, that can potentially
further explain the diﬀerence between progressing to the
less severe form of the disease, dry AMD, or to the more
severe one, wet AMD [26].
Fig. 4. Pathway-based association analysis example output. The pathways are sorted based on z-scores obtained from U-statistics with the linear dosage
kernel.
Fig. 3. Trend test example with highest scoring SNPs in an AMD genome-wide association. The SNPs are sorted based on the second column,
log10 (p-value) for the association test between controls and both case types (dry AMD and wet AMD).
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We have used Pathway/SNP to perform pathway-based
GWA for several diseases. Loading data and updating the
indexes into the database is a complex process and some of
the data loading processes are still performed from the
command line. We are working on creating a GUI-based
data loading mechanism. Since some of the data mining
algorithms can be very computationally intensive, we are
investigating the deployment of Pathway/SNP in a high
performance computing (HPC) cluster environment. (Wehave used Pathway/SNP in a HPC environment from the
command line.)
We are also interested in further developing several anal-
ysis areas of Pathway/SNP, by including:
• environmental factors, such as smoking status, into the
analysis,
• linkage regions from previous studies, as previously sug-
gested [9],
• algorithms, such as Pareto ranking [40], that can rank
pathways by their performance across diﬀerent models,
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as recessive/dominant eﬀect of mutations and chemical
reaction rates,
• functional relevance of SNPs (e.g., non-synonymous
coding SNPs).
The code will be made available at http://
www.dinuinformatics.info.
6. Lessons learned
6.1. The potential need for high performance computation to
support a tool like Pathway/SNP
As described previously, one might attempt to take a
completely brute force approach to analyzing genome-wide
SNP, which would be computationally intractable (as dis-
cussed in Appendix A). Indeed, the various statistical and
data mining approaches described previously in this paper
attempt in diﬀerent ways to avoid such brute force meth-
ods. At the same time, there is clear value to being able
to take advantage of HPC. It is useful to look at the diﬀer-
ent capabilities within Pathway/SNP with regard to the
potential need for high performance computation (e.g.,
the use of parallel clusters of workstations to solve com-
pute-intensive problems).
Table 2 indicates the approximate amount of compute
time required by various Pathway/SNP computations for
the AMD dataset described above. (These ﬁgures were
determined using a single desktop PC with a 1.8 GHz pro-
cessor.) While some of the algorithms complete in a few
minutes, others can be very time consuming, e.g., random
forest with a large number of random trees. When analyz-
ing the statistical signiﬁcance of the scores through permu-
tation-based FDR, the execution times must be multiplied
by the number of permutations. For example, while path-
way ranking using U-statistics completes in 1 min, calculat-
ing the FDR with 1000 permutations will actually complete
in about 1000 min, or about 16.5 h.
As a result, to make a system like Pathway/SNP as
robustly functional as possible, it will be extremely useful
if it could be linked to a HPC facility that could be
utilized for the compute-intensive analyses, as outlined
above.Table 2
Approximate execution times for diﬀerent statistical and data mining
algorithms when applied to the AMD data set (146 individuals genotyped
at 116,204 SNPs; 561 total pathways)
Algorithm Execution time (min)
Single SNP genome-wide association 5
Pathway ranking using U-statistics 1
Pathway ranking using data mining
J48 (C4.5) 8
Naı¨ve Bayes 2
SVM 8
Random forests 200 random trees 4006.2. The need for permutation testing to evaluate the results
of the analysis
Another issue that became clear in the implementation
of Pathway/SNP is that while it is important to allow a
variety of diﬀerent algorithms to be used in analyzing the
data, it is equally important to allow permutation testing
using those algorithms to test the statistical signiﬁcance
of the results obtained. Indeed, there are diﬀerent algo-
rithms that can be used for the permutation testing. Path-
way/SNP currently uses the FDR algorithm, but others are
possible.
An interesting feature of the permutation testing is that
it involves running the analysis algorithm many times, each
time using a diﬀerent set of randomly permuted data based
on the original data set. This shuﬄing of the original data
is commonly performed 1000 or more times. As a result,
from the standpoint of HPC, even algorithms that make
only relatively modest computational demands for the ini-
tial analysis may require HPC to do the required subse-
quent permutation testing. Clearly, when using analysis
algorithms that are already quite computationally inten-
sive, it will often be infeasible to do permutation testing
without HPC.
Pathway/SNP computes permutation-based FDR by
randomly shuﬄing the labels of the individuals and recal-
culating the association statistic using the randomized
data. A potentially interesting alternative approach, which
we did not perform, would be to randomly select sets of
SNPs throughout the genome and calculate a baseline dis-
tribution of scores using these randomly selected SNP sets.
The ﬁrst approach (shuﬄe individual labels) measures how
well a single collection of SNPs, selected in a scientiﬁcally
well founded way—namely, membership in the same path-
way—can be associated with the disease. The second
approach would assess whether arbitrary sets of SNPs
could result in a strong association with the disease.
One possible complication related to the latter approach
of picking random sets of SNPs is that, especially in the
case of high density SNP arrays, the correlation structure
between SNPs might be lost. For example, when one selects
SNPs that are in the vicinity of pathway genes, some of the
SNPs are close genomic neighbors and are likely to be in
linkage disequilibrium and have correlated genotypes. This
correlation between neighboring SNPs would be lost when
selecting random sets of SNPs, randomly dispersed
throughout the genome. To avoid this problem when
applying this approach of selecting random sets of SNPs,
one would need, for example, to use a gene-based approach
with similar gene set sizes.
6.3. Dealing with diﬀerent versions of the biological data and
knowledge
Another important issue that arises when contemplating
using a program like Pathway/SNP on an ongoing basis is
that the various sources of biological data evolve over time.
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‘‘oﬃcial’’ sequence of the human genome has been updated
several times over the past several years. Pathway data is
undergoing the same evolution, as new pathways are added
and as existing pathways are reﬁned. Indeed, when devel-
oping Pathway/SNP, one apparent anomaly in the analysis
arose because several genes that previously had been in a
pathway had been removed in a later version of the path-
way database. It will therefore be important (1) to contin-
ually update the various versions of the diﬀerent sources of
biological data and knowledge that are used, (2) to record
which versions were used for each analysis performed, and
(3) to retain previous versions so that previous calculations
can be checked and veriﬁed.
6.4. Why diﬀerent analysis algorithms might work better
with diﬀerent data sets and diﬀerent diseases
It is well established in the data mining community that
diﬀerent data mining algorithms are frequently found to
work better for diﬀerent data sets in the same basic
domain. This occurs because diﬀerent data sets can exhibit
diﬀerent basic structures that are best uncovered by diﬀer-
ent algorithms. For example, in one data set only one attri-
bute might be suﬃcient to understand the structure of the
data. In another data set, several attributes might contrib-
ute independently to produce an observed eﬀect. In another
data set, a linear combination (or a more complex mathe-
matical relationship) involving a subset of several attri-
butes might be contributing.
Looking at biological processes and disease, one can
hypothesize a number of potential underlying reasons for
such variability in optimal analysis. Some genes act in a
recessive fashion, some in a dominant fashion, and others
in a mixed mode. Sometimes multiple genes must operate
together (in an ‘‘epistatic’’ fashion) to produce dysfunction.
In addition, the exact structure of a pathway (e.g., whether
two genes are ‘‘in series’’ or ‘‘in parallel’’ in a pathway, or
are more complexly interrelated) may aﬀect the nature of
the data and the corresponding success of diﬀerent analytic
approaches. Indeed, one interesting research issue for the
future will be to explore how best to utilize our knowledge
of pathway structure to assist in the more accurate statisti-
cal and data mining analysis of genome-wide SNP associa-
tion data.
6.5. The complexity of the ‘‘Clinical Phenotype’’
An additional issue in building a system like Pathway/SNP
concerns the complexity of the clinical information
included about the patients in a disease association study.
The initial studies that are currently being performed fre-
quently focus on quite extreme manifestations of a disease
in the hope that this may help in producing a strong statis-
tical result. As a result, a study might compare patients
with extreme or malignant hypertension or patients who
had myocardial infarctions before age 40 compared tonormal individuals. Indeed, our AMD dataset focused on
patients with quite large amounts of drusen buildup in
the retina combined with evidence of sight-threatening
dry or wet AMD, which represents a quite extreme form
of the disease. In these cases, the relevant clinical informa-
tion about the patient is by design very limited.
As researchers become more familiar with GWA analy-
sis and start applying the technique to much larger sample
sizes and to common diseases presumed to be multigenic in
etiology, the ‘‘clinical phenotype’’ data relevant to the anal-
ysis may become much more complex. For example, the
clinical phenotype might involve (1) a fairly detailed his-
tory of the progression of a disease with clinical ﬁndings
as various points along the way, and/or (2) a spectrum of
presentations of signs and symptoms involving several
organ systems each with multiple degrees of severity. For
example, the severity of AMD can be classiﬁed on a scale
with ﬁve stages, from 0 (no AMD) to 4 (most advanced
form) [41]. To complicate matters, there are additional
AMD grading scales [42,43], which can make comparing
study results particularly challenging.
For such studies with complex phenotypes, the amount
and complexity of the clinical data that will need to be
include in a system like Pathway/SNP will be much greater
than with current data sets. In addition, the statistical and
data mining analyses of the data will need to be structured
to take advantage of a much more complex clinical pheno-
type. This challenge will raise a host of additional research
issues for the future.
7. Summary
In this paper we introduced Pathway/SNP, a software
program that can perform pathway-based association anal-
ysis between genome-wide high density SNPs and disease.
The software tool integrates domain knowledge—pathway
information, gene and SNP annotation—with statistical
and data mining algorithms. Pathway/SNP can be used
to explore the etiology of complex diseases in a ﬂexible,
interactive, incremental fashion.
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Appendix A
The computational complexityof performing abrute-force
‘‘full-scan’’ interaction analysis between all possible combina-
tions of n genomicmarkers and a disease (or trait) is exponen-
tial in n. Using a set of aboutm = 100,000 genomic markers,
such as the Aﬀymetrix 100k SNP GeneChip, a full-scan for
n = 2 marker interaction would require performing
C(m,n) = 5 · 109 tests; 1.66 · 1014 tests for three markers;
V. Dinu et al. / Journal of Biomedical Informatics 40 (2007) 750–760 7594.16 · 1018 tests for fourmarkers; and 8.33 · 1022 tests for ﬁve
markers (number of subsets of size n in a set of size m). For
comparison, a modern PC (with a clock frequency of a few
GHz) can perform a few 109 ﬂops/s (ﬂops = ﬂoating point
operations), while the fastest supercomputer can perform
about 3.67 · 1014 ﬂops/s (and doubling about each year)
[44]. A simple arithmetic computation shows that performing
a comprehensive scan for association between disease and
four or more interacting markers is virtually impossible with
the current available technology. For example, we found that,
using a 1.8 GHz PC, it takes 5 min to run aGWAanalysis for
single SNPdisease association for 116,204 SNPs and 146 indi-
viduals. Using the same data set and the fastest current super-
computer, we estimate that a test for the interaction of two
markers would take about 1 min; 1 month for three markers;
2000 years for four markers; and 40,000 millennia for ﬁve
markers.
References
[1] Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M,
Mesirov JP, et al. Molecular classiﬁcation of cancer: class discovery
and class prediction by gene expression monitoring. Science
1999;286:531–7.
[2] Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci USA
1998;95:14863–8.
[3] Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple
cancer types by shrunken centroids of gene expression. Proc Natl
Acad Sci USA 2002;99:6567–72.
[4] Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al.
Complement factor H polymorphism in age-related macular degen-
eration. Science 2005;308:385–9.
[5] Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, et al.
A genome-wide association study of nonsynonymous SNPs identiﬁes
a type 1 diabetes locus in the interferon-induced helicase (IFIH1)
region. Nat Genet 2006;38:617–9.
[6] The Wellcome Trust Case Control Consortium website, web site:
http://www.wtccc.org.uk/, date accessed: August 16, 2006.
[7] Storey JD, Akey JM, Kruglyak L. Multiple locus linkage analysis of
genomewide expression in yeast. PLoS Biol 2005;3:e267.
[8] Marchini J, Donnelly P, CardonLR.Genome-wide strategies for detecting
multiple loci that inﬂuence complex diseases. Nat Genet 2005;37:413–7.
[9] Roeder K, Bacanu SA, Wasserman L, Devlin B. Using linkage
genome scans to improve power of association in genome scans. Am J
Hum Genet 2006;78:243–52.
[10] Conti DV, Cortessis V, Molitor J, Thomas DC. Bayesian modeling of
complex metabolic pathways. Hum Hered 2003;56:83–93.
[11] Schaid DJ, McDonnell SK, Hebbring SJ, Cunningham JM, Thibo-
deau SN. Nonparametric tests of association of multiple genes with
human disease. Am J Hum Genet 2005;76:780–93.
[12] Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S,
Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative
phosphorylation are coordinately downregulated in human diabetes.
Nat Genet 2003;34:267–73.
[13] Pang H, Lin A, Holford M, Enerson BE, Lu B, Lawton MP, et al.
Pathway analysis using random forests classiﬁcation and regression.
Bioinformatics 2006;22:2028–36.
[14] Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality
reduction software for detecting gene–gene and gene–environment
interactions. Bioinformatics 2003;19:376–82.
[15] Ritchie MD, Motsinger AA. Multifactor dimensionality reduction
for detecting gene–gene and gene–environment interactions in phar-
macogenomics studies. Pharmacogenomics 2005;6:823–34.[16] Lucek PR, Ott J. Neural network analysis of complex traits. Genet
Epidemiol 1997;14:1101–6.
[17] Motsinger AA, Lee SL, Mellick G, Ritchie MD. GPNN: power
studies and applications of a neural network method for detecting
gene–gene interactions in studies of human disease. BMC Bioinform
2006;7:39.
[18] Bureau A, Dupuis J, Falls K, Lunetta KL, Hayward B, Keith TP,
Van Eerdewegh P. Identifying SNPs predictive of phenotype using
random forests. Genet Epidemiol 2005;28:171–82.
[19] Yoon Y, Song J, Hong SH, Kim JQ. Analysis of multiple single
nucleotide polymorphisms of candidate genes related to coronary
heart disease susceptibility by using support vector machines. Clin
Chem Lab Med 2003;41:529–34.
[20] Yu R, Shete S. Analysis of alcoholism data using support vector
machines. BMC Genet 2005;6(Suppl. 1):S136.
[21] Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ,
Donnelly P. A haplotype map of the human genome. Nature
2005;437:1299–320.
[22] BioCarta website, web site: http://www.biocarta.com/, date accessed:
August 16, 2006.
[23] GenMAPP website, web site: http://www.genmapp.org/, date
accessed: August 16, 2006.
[24] SOAP/WSDL interface for the KEGG system, web site: http://
www.genome.jp/kegg/soap/, date accessed: August 20, 2006.
[25] Entrez Gene website, web site: ftp://ftp.ncbi.nlm.nih.gov/gene/
DATA/, date accessed: August 20, 2006.
[26] Dinu V, Miller PL, Zhao H. Evidence for association between
multiple complement pathway genes and AMD. Genetic Epidemiol-
ogy 2007;31:224–37.
[27] Dinu V, Nadkarni P. Guidelines for the eﬀective use of entity-
attribute-value modeling for biomedical databases. Int J Med Inform
2006.
[28] Armitage P. Tests for linear trends in proportions and frequencies.
Biometrics 1955;11:375–86.
[29] Frank E, Hall M, Trigg L, Holmes G, Witten IH. Data mining in
bioinformatics using Weka. Bioinformatics 2004;20:2479–81.
[30] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a
practical and powerful approach to multiple testing. J Royal Stat Soc.
Series B (Methodol) 1995;57:289–300.
[31] Storey JD, Tibshirani R. Statistical signiﬁcance for genomewide
studies. Proc Natl Acad Sci USA 2003;100:9440–5.
[32] Thakkinstian A, Han P, McEvoy M, Smith W, Hoh J, Magnusson K,
et al. Systematic review and meta-analysis of the association between
complementary factor H Y402H polymorphisms and age-related
macular degeneration. Hum Mol Genet 2006.
[33] Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K,
et al. Variation in factor B (BF) and complement component 2 (C2)
genes is associated with age-related macular degeneration. Nat Genet
2006;38:458–62.
[34] Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of
inﬂammation in the pathogenesis of age-related macular degenera-
tion. Surv Ophthalmol 2006;51:137–52.
[35] Bora PS, Sohn JH, Cruz JM, Jha P, Nishihori H, Wang Y, et al.
Role of complement and complement membrane attack complex in
laser-induced choroidal neovascularization. J Immunol
2005;174:491–7.
[36] Liang FQ, Godley BF. Oxidative stress-induced mitochondrial DNA
damage in human retinal pigment epithelial cells: a possible mech-
anism for RPE aging and age-related macular degeneration. Exp Eye
Res 2003;76:397–403.
[37] Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of
oxidative stress in the pathogenesis of age-related macular degener-
ation. Surv Ophthalmol 2000;45:115–34.
[38] Hoﬀmann S, He S, Jin ML, Masiero L, Wiedemann P, Ryan SJ,
et al. Carboxyamido-triazole modulates retinal pigment epithelial
and choroidal endothelial cell attachment, migration, proliferation,
and MMP-2 secretion of choroidal endothelial cells. Curr Eye Res
2005;30:103–13.
760 V. Dinu et al. / Journal of Biomedical Informatics 40 (2007) 750–760[39] Kindzelskii AL, Elner VM, Elner SG, Yang D, Hughes BA, Petty
HR. Toll-like receptor 4 (TLR4) of retinal pigment epithelial cells
participates in transmembrane signaling in response to photoreceptor
outer segments. J Gen Physiol 2004;124:139–49.
[40] Komuro R, Ford ED, Reynolds JH. The use of multi-criteria
assessment in developing a process model. Ecol Model
2006;197:320.
[41] Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, Lindblad AS,
et al. A simpliﬁed severity scale for age-related macular degenera-
tion: AREDS Report No. 18. Arch Ophthalmol 2005;123:1570–4.[42] Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis
MD, et al. An international classiﬁcation and grading system for
age-related maculopathy and age-related macular degeneration. The
International ARM Epidemiological Study Group. Surv Ophthalmol
1995;39:367–74.
[43] Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The
Wisconsin age-related maculopathy grading system. Ophthalmology
1991;98:1128–34.
[44] top500, web site: http://www.top500.org, date accessed: August 16,
2006.
